Content China Biopharma Out-Licensing Surges to Record $137.7B in 2025, 2026 on Pace to Break It Again 20 February 2026
Podcast How Biotechs Can De-Risk External Manufacturing, Navigate Geopolitical Challenges, and Plan for Capacity Constraints – Dr. Reza Oliyai 9 February 2026
Expert Insight China’s Biotech Ascent Reshapes Global Pharma Strategy, Dominates JPM26 Discussions 19 January 2026
Expert Insight Radioligand Therapy: How China Is Shaping the Future of CDMO Infrastructure 27 March 2020